Paradox Immunotherapeutics

Recent Finacing

Equity

Recent Raise

$10M

Paradox Immunotherapeutics is a preclinical biotech using a lead-identification and validation platform to develop antibodies that selectively target misfolded proteins, pursuing therapies for AL amyloidosis and LECT2.

Founded 2019

Ontario, Canada

1-10

Private

paradoximmuno.com

Highlights

Focus Areas

Biotechnology

Life Science

Pharmaceutical

Recent Investors

Financials

$10M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at Paradox Immunotherapeutics.